Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CHOLOGRAFIN SODIUM is a legacy injectable diagnostic contrast agent approved in 1954 by Bracco, used for radiographic visualization of the biliary system and hepatic function. The exact mechanism and indications are not fully specified in available data, but it represents an older class of iodinated diagnostic imaging agents. This product serves a niche diagnostic imaging market with declining clinical relevance.
Product approaching loss of exclusivity with minimal commercial activity suggests a small, legacy-focused team with limited growth opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CHOLOGRAFIN SODIUM offers minimal career growth; the product is a legacy diagnostic with zero linked job postings and approaching loss of exclusivity. Roles are primarily defensive (maintaining compliance, managing decline) rather than building competitive advantage.
Worked on CHOLOGRAFIN SODIUM at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.